Trials / Not Yet Recruiting
Not Yet RecruitingNCT06178211
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunotherapy: Adebrelimab | Adebrelimab 1200mg Q3W |
| DRUG | chemotherapy: carboplatin plus nab-paclitaxel | carboplatin plus nab-paclitaxel |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-03-01
- Completion
- 2026-11-01
- First posted
- 2023-12-20
- Last updated
- 2023-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06178211. Inclusion in this directory is not an endorsement.